Researchers from the George Washington University discovered that aspirin might have lung-protective impacts and lower the requirement for mechanical ventilation, ICU admission and in-hospital death in hospitalized COVID-19 clients.
George Washington University scientists discovered low dosage aspirin might lower the requirement for mechanical ventilation, ICU admission and in-hospital death in hospitalized COVID-19 clients. Final results suggesting the lung protective impacts of aspirin were released today in Anesthesia & Analgesia.
“As we learned about the connection between blood clots and COVID-19, we knew that aspirin – used to prevent stroke and heart attack – could be important for COVID-19 patients,” Jonathan Chow, MD, assistant teacher of anesthesiology and crucial care medication and director of the Critical Care Anesthesiology Fellowship at the GW School of Medicine and Health Sciences, stated. “Our research found an association between low dose aspirin and decreased severity of COVID-19 and death.”
Over 400 clients confessed from March to July 2020 to healthcare facilities around the United States, consisting of those at GW Hospital, the University of Maryland Medical Center, Wake Forest Baptist Medical Center and Northeast Georgia Health System, were consisted of in the research study. After adjusting for demographics and comorbidities, aspirin usage was connected with a reduced danger of mechanical ventilation (44% decrease), ICU admission (43% decrease), and in-hospital death (47% decrease). There were no distinctions in significant bleeding or obvious apoplexy in between aspirin users and non-aspirin users.
Preliminary findings were very first released as a preprint in fall 2020. Since then, other research studies have actually validated the effect aspirin can have on both avoiding infection and decreasing danger for serious COVID-19 and death. Chow hopes that this research study results in more research study on whether a causal relationship exists in between aspirin usage and lowered lung injury in COVID-19 clients.
“Aspirin is low cost, easily accessible and millions are already using it to treat their health conditions,” stated Chow. “Finding this association is a huge win for those looking to reduce risk from some of the most devastating effects of COVID-19.”
DOI: 10.1213/ANE.0000000000005292
In addition to Chow, research study authors consist of David Yamane, MD, assistant teacher of emergency situation medication and anesthesiology and crucial care medication at the GW School of Medicine and Health Sciences; Ivy Benjenk, Registered Nurse, Miles Per Hour, lead research study planner for the Department of Anesthesiology and Critical Care Medicine at GW Hospital; and Shannon Cain, MD, third-year local in the Department of Emergency Medicine at the GW School of Medicine and Health Sciences; in addition to scientists from the University of Maryland Medical Center, Wake Forest Baptist Medical Center and Northeast Georgia Health System.
